Stock 4547 KISSEI PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Kissei Pharmaceutical Co., Ltd.

Equities

4547

JP3240600001

Pharmaceuticals

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-04-26 am EDT 		5-day change 1st Jan Change
3,585 JPY +1.41% Intraday chart for Kissei Pharmaceutical Co., Ltd. +4.82% +16.02%
Mar. 20 Kissei Pharmaceutical Completes 6 Billion Yen Buyback Program MT
Mar. 19 Tranche Update on Kissei Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 8, 2023. CI

Valuation

Fiscal Period: Marzo 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 135,384 129,918 112,984 117,826 121,792 158,477 - -
Enterprise Value (EV) 1 89,714 72,006 70,273 66,314 73,683 158,477 158,477 158,477
P/E ratio 24.7 x 46.1 x 21.6 x 9.12 x 11.6 x 14.7 x 14.4 x 16.5 x
Yield 1.73% 1.87% 2.2% 2.19% 3.03% 2.29% 2.34% 2.43%
Capitalization / Revenue 1.87 x 2.05 x 1.64 x 1.8 x 1.8 x 2.05 x 1.95 x 1.91 x
EV / Revenue 1.87 x 2.05 x 1.64 x 1.8 x 1.8 x 2.05 x 1.95 x 1.91 x
EV / EBITDA - - 24.3 x - - 9.17 x 11.6 x 11.9 x
EV / FCF 32.1 x 10.8 x -9.52 x - -180 x 11.8 x 11.5 x 17.5 x
FCF Yield 3.12% 9.27% -10.5% - -0.56% 8.44% 8.69% 5.71%
Price to Book 0.74 x 0.68 x 0.52 x 0.59 x 0.63 x 0.77 x 0.76 x 0.75 x
Nbr of stocks (in thousands) 46,716 46,716 46,116 46,116 46,116 44,205 - -
Reference price 2 2,898 2,781 2,450 2,555 2,641 3,585 3,585 3,585
Announcement Date 5/8/19 5/12/20 5/11/21 5/10/22 5/8/23 - - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Marzo 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 72,297 63,234 69,044 65,381 67,493 77,267 81,090 83,082
EBITDA 1 - - 4,653 - - 17,285 13,716 13,318
EBIT 1 6,202 1,857 1,505 -1,402 -1,129 5,767 7,400 7,200
Operating Margin 8.58% 2.94% 2.18% -2.14% -1.67% 7.46% 9.13% 8.67%
Earnings before Tax (EBT) 1 7,121 4,630 7,476 16,507 13,680 15,093 14,653 12,770
Net income 1 5,481 2,817 5,285 12,921 10,528 11,433 11,033 9,630
Net margin 7.58% 4.45% 7.65% 19.76% 15.6% 14.8% 13.61% 11.59%
EPS 2 117.3 60.31 113.2 280.2 228.3 244.1 249.2 217.8
Free Cash Flow 1 4,224 12,037 -11,871 - -678 13,376 13,772 9,050
FCF margin 5.84% 19.04% -17.19% - -1% 17.31% 16.98% 10.89%
FCF Conversion (EBITDA) - - - - - 77.39% 100.4% 67.95%
FCF Conversion (Net income) 77.07% 427.3% - - - 117% 124.82% 93.97%
Dividend per Share 2 50.00 52.00 54.00 56.00 80.00 82.00 84.00 87.00
Announcement Date 5/8/19 5/12/20 5/11/21 5/10/22 5/8/23 - - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2020 S1 2021 S1 2022 Q2 2022 S1 2022 Q3 2023 Q1 2023 Q2 2023 S1 2023 Q3 2024 Q1 2024 Q2 2024 S1 2024 Q3 2025 Q1 2025 S1 2026 S1
Net sales 1 31,548 32,284 15,753 32,388 17,697 16,285 16,579 32,864 18,771 19,313 - 36,978 20,881 20,500 42,500 43,000
EBITDA - - - - - - - - - - - - - - - -
EBIT 1 2,334 2,044 -23 270 -564 130 -755 -625 1,117 1,633 - 2,015 2,149 2,100 5,200 4,800
Operating Margin 7.4% 6.33% -0.15% 0.83% -3.19% 0.8% -4.55% -1.9% 5.95% 8.46% - 5.45% 10.29% 10.24% 12.24% 11.16%
Earnings before Tax (EBT) 2,870 5,711 3,000 7,273 1,440 2,141 2,277 4,418 4,572 4,349 - 7,502 3,598 - - -
Net income 1 2,150 4,396 2,022 5,666 1,153 1,635 1,691 3,326 3,341 3,265 - 5,678 2,659 2,600 5,900 4,200
Net margin 6.82% 13.62% 12.84% 17.49% 6.52% 10.04% 10.2% 10.12% 17.8% 16.91% - 15.36% 12.73% 12.68% 13.88% 9.77%
EPS 2 46.04 94.12 43.85 122.9 25.00 35.47 36.66 72.13 72.45 70.95 52.71 123.7 59.21 58.80 133.5 95.00
Dividend per Share 26.00 27.00 - 28.00 - - - 40.00 - - - 41.00 - - - -
Announcement Date 11/6/19 11/5/20 11/9/21 11/9/21 2/1/22 8/1/22 11/8/22 11/8/22 1/31/23 7/31/23 11/6/23 11/6/23 1/30/24 - - -
1JPY in Million2JPY
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position 45,670 57,912 42,711 51,512 48,109 - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 4,224 12,037 -11,871 - -678 13,377 13,772 9,050
ROE (net income / shareholders' equity) 3.1% 1.5% 2.6% 6.1% 5.3% 5.4% 5.4% 4.57%
ROA (Net income/ Total Assets) 3.36% 1.09% 1.39% 0.22% 0.26% 4.05% 4.85% 4.6%
Assets 1 163,080 258,225 380,605 5,827,620 4,043,011 282,305 227,491 209,348
Book Value Per Share 2 3,901 4,120 4,756 4,367 4,205 4,645 4,729 4,778
Cash Flow per Share 2 173.0 115.0 181.0 361.0 317.0 253.0 238.0 263.0
Capex 1 2,122 1,897 11,139 5,721 2,187 1,770 1,500 1,500
Capex / Sales 2.94% 3% 16.13% 8.75% 3.24% 2.29% 1.85% 1.81%
Announcement Date 5/8/19 5/12/20 5/11/21 5/10/22 5/8/23 - - -
1JPY in Million2JPY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Kissei Pharmaceutical Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
3,585 JPY
Average target price
3,833 JPY
Spread / Average Target
+6.93%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
KISSEI PHARMACEUTICAL CO., LTD. Stock Kissei Pharmaceutical Co., Ltd.
+16.02% 1.01B
MERCK KGAA Stock Merck KGaA
+5.31% 70.44B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+10.97% 8.94B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-16.83% 4.75B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+43.48% 4.5B
YUHAN CORPORATION Stock Yuhan Corporation
+3.20% 3.85B
INDIVIOR PLC Stock Indivior PLC
+18.82% 2.38B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-21.36% 2.34B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-29.67% 2.2B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+8.38% 1.96B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 4547 Stock
  4. Financials Kissei Pharmaceutical Co., Ltd.